Elevated levels of circulating BCAAs are associated with suppressed mitochondrial β-oxidation, reduced glucose tolerance, increased insulin resistance, and increased de novo lipogenesis, making BCAAs a potential biomarker of metabolic disease (Newgard et al., 2009; Weiss and Lustig, 2014). The gene discussed is INS; the disease is Other metabolic disease.